Drug intelligence / Profile preview

SRB5

Development stage: Preclinical
Lead developer: SunRock Biopharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SRB5 is a humanized monoclonal antibody developed to target CCR9, a chemokine receptor highly expressed on immune cells involved in chronic intestinal inflammation. It is designed with enhanced antibody-dependent cellular cytotoxicity (ADCC) properties to selectively deplete CCR9-positive cells. The drug is being investigated primarily for the treatment of inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, and has potential for expansion into other immune-mediated inflammatory conditions and highly aggressive CCR9-expressing tumors.

Targets

CCR9 (C-C chemokine receptor type 9)

Beyond the preview

Go deeper on SRB5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SRB5.

Explore the full profile